Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage Secondary to Diabetic Retinopathy
Overview
- Phase
- Phase 2
- Intervention
- bevacizumab
- Conditions
- Vitreous Hemorrhage Secondary to PDR
- Sponsor
- University of Sao Paulo
- Enrollment
- 1
- Locations
- 1
- Primary Endpoint
- Recurrent vitreous hemorrhage incidence after vitrectomy
- Last Updated
- 16 years ago
Overview
Brief Summary
The purpose of this study is to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without bevacizumab injection.
Detailed Description
Postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative diabetic retinopathy. Bevacizumab (Avastin) is a potent inhibitor of angiogenesis and has been shown to decrease retinal and iris neovascularization in proliferative diabetic retinopathy. We believe that preoperative bevacizumab injection could reduce postoperative vitreous hemorrhage by decreasing the amount of abnormal vessels and intraoperative injection could also reduce postoperative vitreous hemorrhage by inhibiting the vessel formation after surgery
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients undergoing first vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy
Exclusion Criteria
- •follow-up period of less than 3 months
- •not first vitrectomy
- •abnormal blood coagulation
- •uncontrolled hypertension
Arms & Interventions
2- bevacizumab before vitrectomy
Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
Intervention: bevacizumab
3- bevacizumab after vitrectomy
Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
Intervention: bevacizumab
Outcomes
Primary Outcomes
Recurrent vitreous hemorrhage incidence after vitrectomy
Time Frame: 3 months
Secondary Outcomes
- Visual outcome(3 months)